Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 94615496 | 9461549 | 6 | F | 20160822 | 20130816 | 20160823 | EXP | FR-BRISTOL-MYERS SQUIBB COMPANY-19176585 | BRISTOL MYERS SQUIBB | 0.00 | F | Y | 0.00000 | 20160823 | CN | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 94615496 | 9461549 | 1 | PS | REYATAZ | ATAZANAVIR SULFATE | 1 | Transplacental | UNK | U | 21567 | CAPSULE, HARD | ||||||||
| 94615496 | 9461549 | 2 | SS | COMBIVIR | LAMIVUDINEIDOVUDINE | 1 | Transplacental | UNK | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 94615496 | 9461549 | 1 | Product used for unknown indication |
| 94615496 | 9461549 | 2 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 94615496 | 9461549 | DE |
| 94615496 | 9461549 | OT |
| 94615496 | 9461549 | CA |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 94615496 | 9461549 | Foetal exposure during pregnancy | |
| 94615496 | 9461549 | Foetal malformation |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 94615496 | 9461549 | 1 | 20130304 | 0 | ||
| 94615496 | 9461549 | 2 | 20130304 | 0 |